Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Clinical Trial Research Software Provides Range of Trial Capabilities in Unified Platform

By BiotechDaily International staff writers
Posted on 05 Aug 2013
New clinical trial software provides end-to-end study support through a single, easy-to-use interface that allows the ability to manage and run studies more effectively. It offers built-in study templates, libraries, and reports to help users create studies rapidly and manage them effectively without technical help.

Merge Healthcare. Inc. (Chicago, IL, USA), a provider of clinical systems, reported that SGS Life Science Services (Geneva, Switzerland) , a contract service organization with over 35 years’ experience in clinical research, has selected Merge’s eClinical OS to streamline data management across phase I-IV studies.

“SGS sought a comprehensive EDC solution that would still be cost-effective for our biotech and smaller pharmaceutical clients,” explained Joris De Bondt, head of EDC and data standards of clinical research at SGS Life Science Services. “More specifically, we needed a system that included interactive response and drug dispensing in addition to data capture functionality. We were pleased to find that Merge’s eClinical OS includes such a broad set of capabilities. Using one system for everything needed maximizes efficiency and improves timelines across all our studies.”

“As one of the premier global CROs in the industry, we’re very pleased to have SGS as a partner,” said Zaher El-Assi, general manager of Merge eClinical. “We find that our CRO partners benefit greatly from training and ongoing support through the Merge Certified Designer program. Our goal is to empower our CRO partners to better serve their customers by developing internal expertise to quickly build, test, and deploy trials for their organization regardless of trial complexity and size.”

“We were most impressed with the ability to tailor the system for each study depending on the features needed. The unique pay-as-you go model provides us with more cost efficiencies that we are then able to pass along to our clients,” explained Mr. De Bondt. “Another benefit was how straight-forward the system was to use. Our team was able to learn the system, build a complete trial and have the trial validated and pass user acceptance testing faster than with previous systems.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more efficiently than ever before. The system works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality at any time.

Merge also provides clinical trials software, health stations, and other health data and analytics solutions that engage consumers in their personal health.

SGS Life Science Services is a contract service organization (CSO) providing clinical research, biologics characterization, biosafety, and quality control (QC) testing. SGS provides pharmaceutical companies with phase I-IV clinical trial management services encompassing clinical project management and monitoring, pharmacokinetic/pharmacodynamic (PK/PD) simulation and modeling services, data management, biostatistics, and regulatory consultancy.


Related Links:
Merge Healthcare
SGS Life Science Services


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.